TNX 1800 is a live modified horsepox virus vaccine for percutaneous administration, being developed by Tonix Pharmaceuticals, in collaboration with Southern Research, for the prevention of COVID-2019 infections. The company is using its proprietary horsepox virus technology that developed vaccine engineered to express relevant protein antigens from the virus that causes COVID-19. The horsepox has the potential to serve as a vector for vaccines to protect against other infectious agents. TNX 1800 is designed to express the spike protein from the virus that causes COVID-19 (SARS-CoV-2) and to induce T cell response. The protein synthesis connected with a replicating live virus vaccine provides direct antigen presentation, which stimulates cellular immunity in addition to humoral immunity. Preclinical development is underway in the US.
In February 2020, Tonix Pharmaceuticals entered into a research and development collaboration with Southern Research to develop TNX 1800 for the prevention of COVID-2019 infections, based on Tonix’s proprietary horsepox vaccine platform. Under the terms of the agreement, Southern Research will test one or more vaccine constructs in the Tonix horsepox vector that express one or more proteins or protein fragments from the virus that causes COVID-19. The collaboration seeks to leverage Tonix’s horsepox vaccine technology originally developed to protect against smallpox but has capabilities as a vector for other infectious diseases. 
Key Development Milestones
As of February 2020, modified horsepox virus vaccine was in pre-IND stage of the development   .
As of May 2020, Tonix Pharmaceuticals has filed a provisional patent for technology related to TNX 1800 (Tonix Pharmaceuticals website, May 2020).